EVALUATE LIMITED

Active London
0 employees website.com
Life sciences and medical technology
E

EVALUATE LIMITED

Founded 14 Jul 2006 Active London, United Kingdom 0 employees website.com
Life sciences and medical technology

Previous Company Names

EVALUATEPHARMA LIMITED 14 Jul 2006 — 25 Oct 2012
Accounts Submitted 28 Aug 2025 Next due 30 Sept 2026 5 months remaining
Confirmation Submitted 13 May 2025 Next due 13 May 2026 18 days remaining
Net assets £35M £19M 2024 year on year
Total assets £103M £22M 2024 year on year
Total Liabilities £68M £3M 2024 year on year
Charges 5
2 outstanding 3 satisfied

Contact & Details

Contact

Registered Address

3 More London Riverside London SE1 2AQ United Kingdom

Telephone

0800 000 0000

Email

info@example.com

Website

www.example.com

Full company profile for EVALUATE LIMITED (05876322), an active life sciences and medical technology company based in London, United Kingdom. Incorporated 14 Jul 2006. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type Total Exemption Full
Next accounts 31 December 2025
Due by 30 September 2026 9 months

Balance Sheet & P&L (2014–2024)

Cash in Bank

£3.97M

Decreased by £8.72M (-69%)

Net Assets

£35.36M

Increased by £18.78M (+113%)

Total Liabilities

£67.72M

Increased by £2.77M (+4%)

Turnover

£79.04M

Increased by £10.58M (+15%)

Employees

N/A

Decreased by 157 (-100%)

Debt Ratio

66%

Decreased by 14 (-18%)

Financial History

Revenue, profit, EBITDA and key financial figures

2024
Dec Year End
2023
Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

Funding Rounds 2

Investors (2)

Investor NameInvestor SinceParticipating Rounds
Investor 2Nov 2016Private Equity
Investor 1Aug 2020Private Equity

Officers

Officers

0 active 3 resigned
Status

No officers found

No officers found

Shareholders

Shareholders (1)

Caerus Uk 1 Limited
100.0%
100

Persons with Significant Control

Persons with Significant Control (1)

1 Active 3 Ceased

Caerus Uk 1 Limited

United Kingdom

Active
Notified 27 Dec 2023
Nature of Control
  • Ownership Of Shares 75 To 100 Percent,voting Rights 75 To 100 Percent,right To Appoint And Remove Directors

Evaluate Group Limited

Ceased 2 Nov 2016

Ceased

Evaluate Newco Limited

Ceased 21 Jun 2021

Ceased

Evaluate Group Limited

Ceased 27 Dec 2023

Ceased

Group Structure

Group Structure

CAERUS UK 1 LIMITED united kingdom
EVALUATE LIMITED Current Company

Charges

Charges

2 outstanding 3 satisfied

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
28 Aug 2025AccountsAnnual accounts made up to 2024-12-31
13 May 2025Confirmation StatementConfirmation statement made on 2025-04-29 with no updates
18 Feb 2025OfficersTermination of Levine Chris Randiga as director on 2025-02-04
18 Feb 2025OfficersAppointment of Kevin Joseph Mccurry as director on 2025-02-04
23 Dec 2024OfficersTermination of Kevin Stephen Morgan as director on 2024-12-20
28 Aug 2025 Accounts

Annual accounts made up to 2024-12-31

13 May 2025 Confirmation Statement

Confirmation statement made on 2025-04-29 with no updates

18 Feb 2025 Officers

Termination of Levine Chris Randiga as director on 2025-02-04

18 Feb 2025 Officers

Appointment of Kevin Joseph Mccurry as director on 2025-02-04

23 Dec 2024 Officers

Termination of Kevin Stephen Morgan as director on 2024-12-20

Recent Activity

Latest Activity

Annual accounts made up to 2024-12-31

7 months ago on 28 Aug 2025

Confirmation statement made on 2025-04-29 with no updates

11 months ago on 13 May 2025

Termination of Levine Chris Randiga as director on 2025-02-04

1 years ago on 18 Feb 2025

Appointment of Kevin Joseph Mccurry as director on 2025-02-04

1 years ago on 18 Feb 2025

Termination of Kevin Stephen Morgan as director on 2024-12-20

1 years ago on 23 Dec 2024